comparemela.com

Page 2 - Bergenbio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BerGenBio ASA: BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

- The Company will discuss the topline results during its Q4 2022 results presentation on Thursday, February 16, 2023, at 10:00 AM CET - BERGEN, Norway, Feb. 15, 2023 /PRNewswire/ BerGenBio

United statesUnited kingdomCity ofDennis riedlGraham morrellJan lillebyMartin olinJames spicerPrnewswire bergenbioInvestor relations international mediaCo incOslo stock exchangeNon small cell lung cancerChief executive officerExperimental cancer medicineCollege london

BerGenBio ASA: BerGenBio Announces the Establishment of Oncology Scientific Advisory Board

- Distinguished global experts appointed to strengthen bemcentinib development in STK11m NSCLC - BERGEN, Norway, Feb. 2, 2023 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage

United statesUnited kingdomComunidad autonoma de catalunaJan lillebyMartin olinSchwierige zeitenJohn heymachGraham morrellTony mokCristina olivaEnriqueta felipPrnewswire bergenbioSolange petersUniversity of albertaNational cancer instituteAmerican society of clinical oncology

BerGenBio ASA: BerGenBio reports third quarter 2022 financial results and provides business update

- Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 mutations Strengthened

United kingdomGraham morrellMartin olinPrnewswire bergenbioLinstitut national de la santOslo university hospitalClinical developmentEuropean clinical research infrastructure networkOslo stock exchangeChief executive officerNon small cell lung cancerFinancial reportsAbuse regulationNorwegian securities trading

BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS

BERGEN, Norway, Oct. 25, 2022 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical

United kingdomGraham morrellMartin olinPrnewswire bergenbioOslo stock exchangeNon small cell lung cancerChief executive officerAbuse regulationNorwegian securities trading

BerGenBio ASA: BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS

BERGEN, Norway, Sept. 27, 2022 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical

United kingdomGraham morrellMartin olinPrnewswire bergenbioLinstitut national de la santOslo university hospitalEuropean clinical research infrastructure networkOslo stock exchangeEuropean discoveryEmerging infection platform trialChief executive officerChief investigatorSenior consultantOslo universityUniversity hospitalNorwegian securities trading

vimarsana © 2020. All Rights Reserved.